Ongoing reporting underscores that CAR-T therapy economics and access are constrained not only by efficacy but by manufacturing capacity, donor-to-donor variability, and multi-step GMP workflows. The coverage highlights that the bottleneck has shifted from initial clinical validation toward scalable delivery and real-time manufacturing visibility. The manufacturing challenge is amplified by limited inline analytics and the reliance on downstream measurements, which reduces the ability to intervene early when production deviates. This environment is spurring platform development aimed at predictive control and earlier detection of cellular state shifts during manufacturing. For biotech leaders, the message is direct: expanding CAR-T patient access increasingly depends on reducing cost and improving throughput via predictive manufacturing intelligence, not solely by adding automation.